♫musicjinni

James Bradner, MD President, Novartis Institutes for BioMedical Research
video thumbnail
Download MP3 ⤋Download MP4 ⤋
Yale Cancer Center Grand Rounds: January 15, 2018
The End of Undruggable

At the Crossroads of Epigenetics and Angiogenesis Targeting the Undruggable

The State of Yale Cancer Center and Smilow Cancer Hospital: 2019-2020

Yale Cancer Center Grand Rounds | February 28, 2023

Defining Mechanisms and Biomarkers of Sensitivity & Resistance To Anti-Cancer Treatments

James Bradner, MD President, Novartis Institutes for BioMedical Research

The KRAS Variant and Cancer Risk

Yale Cancer Center Grand Rounds | May 4, 2021

Yale Cancer Center Grand Rounds | June 22, 2021

Smilow Shares: World Pancreatic Cancer Day

Data on KRAS inhibitors in lung cancer at WCLC 2022

YCC Functional Genomics Core

April 20, 2021 | Smilow Shares: Understanding the Latest Treatment Advances in Head and Neck Cancers

Tales of Genomic Instability

June 10, 2020 | Smilow Patient and Family Forum: Partnering in your Care

Cereblon and GSPT1 degrader in refractory/relapsed AML

"Immuno-Oncology Targets in African American Cancer Patients"

On the Cutting Edge: Research Toward a Cure for Colorectal Cancer

Undruggable: The Next Wave of Drug Development

Christopher Austin, MD

The Atlantic and Amgen Oncology Present: Cautiously Close, Inside the Race Against Cancer

Dr. Roy S. Herbst: Update on Lung Cancer Treatment

Axiom AACR Townhall with Dr. Patricia LoRusso

Genetically Tailored Therapy for Pancreatic Cancer

AllyCon 2020: Advances in Precision Treatment and Therapies for Colorectal Cancer

Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum

Oncotarget: Alternative RNA Splicing in Pancreatic Cancer

Clinical Proteogenomic Tumor Analysis Consortium

Company Profile: Arvinas

May 4, 2021 - Luke Hoeppner, PhD

GenLive The Next Wave of Cancer Treatments (Sponsor: Isoplexis)

Disclaimer DMCA